Application of physiologically based pharmacokinetic modeling in the prediction of pharmacokinetics of bicyclol controlled-release formulation in human

European Journal of Pharmaceutical Sciences

Volumn 77, Issue , 2015, Pages 265-272

  Wang, Baolian ^a   Liu, Zhihao ^a   Li, Dan ^a   Yang, Shuang ^a   Hu, Jinping ^a   Chen, Hui ^a   Sheng, Li ^a   Li, Yan ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Bicyclol; Dog; Human; PBPK; Pharmacokinetic

Indexed keywords

ANTIVIRUS AGENT; BICYCLOL; UNCLASSIFIED DRUG; BIPHENYL DERIVATIVE; DELAYED RELEASE FORMULATION;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; BEAGLE; CONTROLLED RELEASE FORMULATION; DISSOLUTION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG RELEASE; DRUG SOLUBILITY; EXPERIMENTAL DOG; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MATHEMATICAL MODEL; NONHUMAN; OSMOTIC PUMP; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TABLET; ANIMAL; BIOLOGICAL MODEL; DELAYED RELEASE FORMULATION; DOG;

ANIMALS; BIPHENYL COMPOUNDS; DELAYED-ACTION PREPARATIONS; DOGS; HUMANS; MODELS, BIOLOGICAL;

EID: 84934278553     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2015.06.020     Document Type: Article

References (33)

1. B. Agoram, W.S. Woltosz, and M.B. Bolger Predicting the impact of physiological and biochemical processes on oral drug bioavailability Adv. Drug Deliver. Rev. 50 Suppl. 1 2001 S41 S67
2. G. Allan, J. Davis, M. Dickins, I. Gardner, T. Jenkins, H. Jones, R. Webster, and H. Westgate Pre-clinical pharmacokinetics of UK-453,061, a novel non-nucleoside reverse transcriptase inhibitor (NNRTI), and use of in silico physiologically based prediction tools to predict the oral pharmacokinetics of UK-453,061 in man Xenobiotica 38 2008 620 640
3. P.J. Bungay, S. Tweedy, D.C. Howe, K.R. Gibson, H.M. Jones, and N.M. Mount Pre-clinical and clinical pharmacokinetics of PF-02413873, a non-steroidal progesterone receptor antagonist Drug Metab. Dispos. 39 2011 1396 1405
4. S.S. De Buck, V.K. Sinha, L.A. Fenu, M.J. Nijsen, C.E. Mackie, and R.A. Gilissen Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs Drug Metab. Dispos. 35 2007 1766 1780
5. Guo, M., Lv, Z., Li, Y., Pan, X., Yang, C., Li, Q., Wang, X., Lan, P., Zhao, L., Liu, Y., Liu, Y., 2012. Double-layer Osmotic Pump Controlled Release Tablet of Bicyclol and Preparation Method Thereof. EP2471521 A1.
6. Y. Han, J.P. Shi, A.L. Ma, Y. Xu, X.D. Ding, and J.G. Fan Randomized, vitamin E-controlled trial of bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose Clin. Drug Invest. 34 2014 1 7
7. W. Huang, S.L. Lee, and L.X. Yu Mechanistic approaches to predicting oral drug absorption AAPS J. 11 2009 217 224
8. P.K. Jha, and R.G. Larson Assessing the efficiency of polymeric excipients by atomistic molecular dynamics simulations Mol. Pharm. 11 2014 1676 1686
9. Y. Ji, N. Cheng, and G. Yao Pharmacokinetic study of bicyclol in thirty health volunteers Chin. J. Clin. Pharmacol. Therap. 6 2001 219 222
10. M. Kuentz, S. Nick, N. Parrott, and D. Röthlisberger A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study Eur. J. Pharm. Sci. 27 2006 91 99
11. G.T. Liu Bicyclol: a novel drug for treating chronic viral hepatitis B and C Med. Chem. 5 2009 29 43
12. Lv, Z., Zhang, Y., Li, Q., Lan, P., Pan, X., Zhao, L., 2009. Bicyclol Pharmaceutical Compositions Containing Surfactant and its Preparations Method Thereof. CN 101390851A.
13. V. Papadopoulou, K. Kosmidis, M. Vlachou, and P. Macheras On the use of the Weibull function for the discernment of drug release mechanisms Int. J. Pharm. 309 2006 44 50
14. C.N. Patra, S. Swain, J. Sruti, A.P. Patro, K.C. Panigrahi, S. Beg, and M.E. Rao Osmotic drug delivery systems: basics and design approaches Recent Pat. Drug Deliv. Formul. 7 2013 150 161
15. P. Poulin, and F.P. Theil A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drug discovery J. Pharm. Sci. 89 2000 16 35
16. P. Poulin, K. Schoenlein, and F.P. Theil Prediction of adipose tissue: plasma partition coefficients for structurally unrelated drugs J. Pharm. Sci. 90 2001 436 447
17. S.M. Rahman, T.C. Telny, T.K. Ravi, and S. Kuppusamy Role of surfactant and pH in dissolution of curcumin Indian J. Pharm. Sci. 71 2009 139 142
18. T. Rodgers, and M. Rowland Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions J. Pharm. Sci. 95 2006 1238 1257
19. T. Rodgers, D. Leahy, and M. Rowland Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases J. Pharm. Sci. 94 2005 1259 1276
20. T. Rodgers, D. Leahy, and M. Rowland Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat J. Pharm. Sci. 94 2005 1237 1248
21. J.K. Ryu, and S.D. Yoo Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability Drug Dev. Ind. Pharm. 38 2012 1313 1318
22. R. Sareen, N. Jain, and D. Kumar An insight to osmotic drug delivery Curr. Drug Deliv. 9 2012 285 296
23. C.E. Shardlow, G.T. Generaux, A.H. Patel, G. Tai, T. Tran, and J.C. Bloomer Impact of physiologically based pharmacokinetic modeling and simulation in drug development Drug Metab. Dispos. 41 2013 1994 2003
24. L. Sheng, J. Hu, B. Wang, H. Chen, and Y. Li Determination of bicyclol in dog plasma using liquid chromatography-tandem mass spectrometry J. Chromatogr. B 878 2010 2106 2110
25. M.R. Shiran, N.J. Proctor, E.M. Howgate, K. Rowland-Yeo, G.T. Tucker, and A. Rostami-Hodjegan Prediction of metabolic drug clearance in humans: in vitro-in vivo extrapolation vs allometric scaling Xenobiotica 6 2006 567 580
26. H. Sun, L. Yu, H. Wei, and G. Liu A novel antihepatitis drug, bicyclol, prevents liver carcinogenesis in diethylnitrosamine-initiated and phenobarbital-promoted mice tumor model J. Biomed. Biotechnol. 2012 2012 584728
27. C. Wang, M.Y. Peeters, K. Allegaert, H.J. Blussé van Oud-Alblas, E.H. Krekels, D. Tibboel, M. Danhof, and C.A. Knibbe A bodyweight-dependent allometric exponent for scaling clearance across the human life-span Pharm. Res. 29 2012 1570 1581
28. H. Wen, and K. Park Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice 2010 John Wiley & Sons New Jersey
29. W. Xie, G. Shi, H. Zhang, G. Zhao, Z. Yu, Z. Lang, H. Zhao, J. Yan, and J. Cheng A randomized, multi-central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol Hepatol. Int. 6 2012 441 448
30. S. Yamazaki, J. Skaptason, D. Romero, S. Vekich, H.M. Jones, W. Tan, K.D. Wilner, and T. Koudriakova Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one compartment model Drug Metab. Dispos. 39 2011 383 393
31. X. Zhang, R.A. Lionberger, B.M. Davit, and L.X. Yu Utility of physiologically based absorption modeling in implementing quality by design in drug development AAPS J. 13 2011 59 71
32. H. Zhang, B. Xia, J. Sheng, T. Heimbach, T.H. Lin, H. He, Y. Wang, S. Novick, and A. Comfort Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect AAPS PharmSciTech. 15 2014 400 406
33. Y.H. Zhao, M.H. Abraham, J. Le, A. Hersey, C.N. Luscombe, G. Beck, B. Sherborne, and I. Cooper Rate-limited steps of human oral absorption and QSAR studies Pharm. Res. 19 2002 1446 1457